Health Care Equipment

Talis Biomedical

PicoCELA

Agape ATP

Co-Diagnostics

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long QBTS Daily ETF

Akanda

Netcapital

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Liminatus Pharma

BTAI

TBIO

TLIS

ARKG

Biotalys revealed significant business milestones and financial performances for the year 2025. The company reported a total revenue of $XX million, marking a XX% growth from the previous year. Additionally, their net income reached $XX million, highlighting a XX% increase compared to 2024. Looking ahead to 2026, Biotalys provided a positive outlook, anticipating further growth and expansion in their operations.

Unusual Whales

Bioxcel Therap

Telesis Bio

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Biotalys Reports Full-Year 2025 Financial Results and Business Highlights

During the complimentary webinar, participants can learn how to assess AI technologies based on their reliability, safety, and regulatory compliance. The session will provide guidance on identifying AI applications that can effectively streamline processes for sponsors and sites currently, as well as pinpointing areas where human intervention is essential. Join to gain valuable knowledge on leveraging AI effectively in the industry.

iShares Global Healthcare

SPDR S&P Health

Health Care Select Sector SPDR

VG Health

iShares US Healthcare Providers

Using AI to Responsibly Accelerate Clinical Trials Under Regulatory Scrutiny, Upcoming Webinar Hosted by Xtalks

Inturai (CSE: URAI / OTC: URAIF / FSE: 3QG0) through investor@inturai.com has demonstrated progress in its partnership with Talius with ongoing cooperation. The aim is to achieve a total revenue of USD $2.5 million within the first three years of collaboration and referrals. This collaboration further enhances the capabilities offered by Talius.

INTURAI Ventures and Talius sign LOI for AI-powered sensing and spatial intelligence tech, targeting $2.5M revenue over 3 years.

Inturai Ventures Corp. has signed a non-binding Letter of Intent (LoI) with Talius Group Limited to integrate AI-powered sensing and spatial intelligence technology into Talius' Smart Care platform. This collaboration aims to generate USD $2.5 million in revenue over three years through direct deployment and referrals. The partnership focuses on enhancing care capabilities and situational awareness in healthcare settings. A definitive agreement is being negotiated, with a joint steering committee overseeing the integration process.

StockTitan

INTURAI VENTURES AND TALIUS SIGN LOI FOR ROLLOUT OF AI-POWERED SENSING AND SPATIAL INTELLIGENCE TECHNOLOGY | URAIF Stock News

Talis Biomedical(TLIS.US)

Biotalys Reports Full-Year 2025 Financial Results and Business Highlights

Using AI to Responsibly Accelerate Clinical Trials Under Regulatory Scrutiny, Upcoming Webinar Hosted by Xtalks

INTURAI Ventures and Talius sign LOI for AI-powered sensing and spatial intelligence tech, targeting $2.5M revenue over 3 years.

INTURAI VENTURES AND TALIUS SIGN LOI FOR ROLLOUT OF AI-POWERED SENSING AND SPATIAL INTELLIGENCE TECHNOLOGY | URAIF Stock News